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Abstract
A substantial number of individuals have long-lasting adverse effects from a traumatic brain injury (TBI).
Depression is one of these long-term complications that influences many aspects of life. Depression can
limit the ability to return to work, and even worsen cognitive function and contribute to dementia. The
mechanistic cause for the increased depression risk associated with a TBI remains to be defined. As TBI
results in chronic neuroinflammation, and priming of glia to a secondary challenge, the inflammatory
theory of depression provides a promising framework for investigating the cause of depression following a
TBI. Increases in cytokines similar to those seen in depression in the general population are also increased
following a TBI. Biomarker levels of cytokines peak within hours-to-days after the injury, yet pro-inflammatory cytokines may still be elevated above physiological levels months-to-years following TBI, which
is the time frame in which post-TB! depression can persist. As tumor necrosis factor a and interleukin 1
can signal directly at the neuronal synapse, pathophysiological levels of these cytokines can detrimentally
alter neuronal synaptic physiology. The purpose of this review is to outline the current evidence for the
inflammatory hypothesis of depression specifically as it relates to depression following a TBI. Moreover,
we will illustrate the potential synaptic mechanisms by which tumor necrosis factor a and interleukin 1
could contribute to depression. The association of inflammation with the development of depression is
compelling; however, in the context of post-TB! depression, the role of inflammation is understudied. This
review attempts to highlight the need to understand and treat the psychological complications of a TBI,
potentially by neuroimmune modulation, as the neuropsychiatric disabilities can have a great impact on
the rehabilitation from the injury, and overall quality of life.
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Introduction
Traumatic brain injury (TBI) is a public health crisis, which
by conservative estimates, affects 1. 7 million Americans each
year (National Center for Injury Prevention and Control,
2003; Faul et al., 2010) . Consequences of brain injury are
known to increase in prevalence proportionally to the severity of the TBI and with increasing instances of TBI. Some
of these consequences include physical disability, memory
impairments, and mood disorders (Blennow et al., 2016). In
addition, factors such as age at the time of injury, sex, and
genetic predisposition are associated with increased longterm complications from the TBI (Blennow et al., 2016).
As many as 90% of TBis are classified as concussions, or
mild TBI (Blennow et al., 2016). The vast majority of the
time (80-90%), symptoms of the mild TBI will resolve within the first two weeks after the injury (Blennow et al., 2016).
Even with the resolution of symptoms in the vast majority
of people following a mild TBI, there is compelling evidence
that progressive brain atrophy, as well as cognitive dysfunction, continue after a mild TBI (Gardner and Yaffe, 2015;
Rabinowitz et al., 2015; Theadom et al., 2018). For those

people with a mild TBI that have symptoms unresolved for
longer than three months, the individuals are diagnosed
with post-concussive syndrome. The symptoms associated
with the post-concussive syndrome are varied and subjective: including sleep disturbances, headache, and mood
disorders, such as anxiety, irritability, and depression (Blennow et al., 2016). Repeated brain injuries can increase the
prevalence and severity of post-concussive symptoms and
may lead to a neurodegenerative condition called chronic
traumatic encephalopathy (CTE), which is a pathologically
diagnosed disease.
Memory impairments, sleep disturbances, headache, and
mood disorders caused by TBI are highly interrelated. Treatment in one area following TBI may be beneficial in improving other symptoms. For example, treating depression can
reduce memory impairments, overall disability, and improve
quality of life (Kumar et al., 2018). Among the various cognitive disturbances following mild TBI, depression severity
is strongly associated with overall disability following a mild
TBI (Mac Donald et al., 2017) and is more common in people that suffered a TBI compared to the general population
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(Blennow et al., 2016).
In general, responsiveness to depression treatment is typically inconsistent (Belmaker and Agam, 2008), and may be
even more so for depression associated with a TBI (Blennow
et al., 2016) . For example, while prior anecdotal evidence
has suggested that depression in individuals with a history
of TBI are responsive to anti-depression medication, recent
results show this may not always be the case. Specifically,
a recent randomized controlled trial found that a selective
serotonin reuptake inhibitor (SSRI), Sertraline (trade name:
Zoloft), was no more effective than placebo in people with
depression following a TBI (Fann et al., 2017). This single
trial does not prove, or even suggest, that individuals with
depression and a history of TBI will not benefit from an
SSRI or other anti-depression medication. It is possible that
depression associated with TBI is more likely to be treatment-resistant, but to the best of our knowledge, this association has not been tested.
Depression does not arise from a single known pathogenic
mechanism (Belmaker and Agam, 2008). A prior history of
mood disorder and other comorbidities, such as substance
abuse, psychosocial factors, and cardiovascular disease may
contribute to the risk of developing depression following a
TBI (Blennow et al., 2016). However, without a complete
understanding of the pathophysiological mechanism(s) that
lead to depression following TBI, targeted disease-modifying therapies cannot be developed.
While a specific mechanism has not been established, accumulating evidence indicates that inflammatory pathways
may contribute to the development of depression, at least
in a subset of patients (Miller and Raison, 2016). Given that
inflammation can persist for years after a TBI (Ramlackhansingh et al., 2011; Coughlin et al., 2017), it is logical to
speculate that the chronic low-grade inflammation seen after
a TBI could be mechanistically linked to the high rates of depression following a TBI. In recent years, a limited number
of studies have provided intriguing preliminary evidence of
a link between TBI-induced inflammatory biomarkers in the
cerebrospinal fluid (CSF) and increased odds of developing
depression (Juengst et al., 2015), as well as an increased association with suicidal endorsement (Juengst et al., 2014), and
post-traumatic stress disorder (PTSD) (Speer et al., 2018).
The objective of this review is to discuss the current evidence for the inflammatory hypothesis of depression, as
it relates to post-TBI depression. We will first describe the
evidence for both acute and chronic inflammatory cytokine
changes following a TBI. We will then summarize the prevalence of depression following TBI. Linking cytokines and
depression, we will then provide a general overview of the
inflammatory hypothesis of depression. Then focusing on
the IL-1, and TNFa pathways, two of the cytokines which
have been most consistently shown to be dysregulated by a
TBI, we will summarize the potential cellular and molecular
mechanisms of those cytokines that may contribute to postTBI depression. As a whole, the concept of anti-inflammatory therapy for depression is compelling, but largely unexplored, particularly in the context of post-TB! depression.

By summarizing the state of the field, we hope to stimulate
inquiries into the inflammatory theory of post-TB! depression, as a promising area of treatment for the chronic complications of TBI.

Cytokine Changes Associated With a TBI
The inflammatory response to a TBI has been the subject of
many in-depth reviews, and we recommend the following
reviews for readers who would like a more general overview
of neuroinflammation following TBI (Witcher et al., 2015;
Burda et al., 2016; Faden et al., 2016; Hellewell et al., 2016;
Loane and Kumar, 2016; Jassam et al., 2017; Simon et al.,
2017; Ziebell et al., 2017; Kokiko-Cochran and Godbout,
2018). The goal of the current review is to highlight the
function of inflammatory cytokines as a critical mediator of
the inflammatory effects on neuronal dysfunction as it relates to post-TB! depression, and as such we will not provide
a general overview of neuroinflammation.
Cytokines are a category of signaling proteins that act
via binding to specific receptors. The dominant effects of
cytokines occur by cell-to-cell interaction in the local tissue environment via paracrine signaling, or even acting on
the releasing cell in an autocrine manner (Gulati, 2009).
Chemokines, which are a subclass of cytokines, in contrast,
have more global effects with important endocrine functions
such as establishing gradients to chemoattract cells to the
appropriate target.
Neurotransmitters were once thought to only act in the
nervous system and cytokines were thought to be restricted
to the immune system; however, there is now resounding
evidence that both neurotransmitters and cytokines are
used in both the nervous and immune systems (Liu and
Quan, 2018). For example, in the brain, interleukin (IL)1 is largely produced by microglia and astrocytes (Liu and
Quan, 2018); interestingly, the receptor for IL-1 is found on
endothelial cells and neurons (Liu and Quan, 2018). Recent
evidence suggests that there is heterogeneity in the class of
neurons that express the receptor for IL-1 (Liu and Quan,
2018). Thus, there is an exciting possibility that expression
of different cytokine receptors may define unique subtypes
of neurons and provide an additional level modulatory information at the level of synaptic transmission.
Cytokines historically have been linked to the innate and
adaptive immune system where they are involved in defense
against pathogens (Gulati, 2009). In the healthy organism,
cytokines are produced at very low levels, but in response to
activating stimulus (i.e., pathogen, or tissue damage) levels
of cytokines can be rapidly induced to levels greater than a
100-fold of that found at the basal condition. This property
of rapid and robust induction has caused cytokines to be a
very active area for biomarker research, as we will describe
in the following paragraph. The dramatic increase in cytokines after an activating stimulus is limited in time as high
levels of circulating cytokines, such as in sepsis, can be fatal. The mechanisms for temporally and spatially limiting
the cytokine response include, for example, unstable RNA
(Stumpo et al., 2010; Vlasova-St Louis and Bohjanen, 2014),
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short half-life of the cytokine proteins, anti-inflammatory
cytokines (i.e., IL-4 and IL-10), receptor internalization,
degradation or shedding, decoy receptors (IL-1R2), and
receptor antagonists (IL-Ira) (Garlanda et al., 2013). Thus,
cytokines whisper to neighboring cells when conditions are
good, but when things are not good, they can also yell.
To measure cytokine changes in people after a TBI four
approaches have been used, including measuring cytokines
in blood, cerebrospinal fluid (CSF), microdialysate, and
biopsy or postmortem brain tissue. Blood biomarker measurements are the least invasive approach, with levels of
cytokines determined in either serum, plasma, and in some
instances by stimulating circulating immune cells with a
mitogen. In the case of moderate-to-severe TBI, CSF that
would otherwise be discarded during the management of
intracranial pressure is collected for biomarker assays. Cerebral microdialysis probes are capable of sampling the local
brain parenchymal concentrations of cytokines, and other
molecules, but must be neurosurgically implanted (Helmy et
al., 2011).
A few technical considerations must be taken into account
when interpreting cytokine biomarker changes after an injury. The sensitivity of the assay used to measure the cytokines
can affect the ability to detect low levels of cytokines. In our
own experience, we have found that multiplex cytokine kits
from different companies or even new versions of the kit
from the same company can find different results concerning which cytokine is most abundantly expressed after an
injury and if certain cytokines can be detected or not. Differences in processing the samples can result in degradation of
the cytokines. How often the CSF is sampled, for example,
can affect the ability to detect cytokine changes after TBI
(Shore et al., 2004). Microdialysis can measure tissue levels
of cytokines, but the probe itself can induce inflammation,
and the location of the probe in relation to the areas of the
brain that are injured can influence the results (Helmy et al.,
2009). Regardless of which method is used to measure cytokine levels, there is clear evidence that cytokines are elevated
following a TBI, as we describe below.
Only a few studies have reported cytokine changes in
people following mild TBI (Mukherjee and Mobry, 1979;
Ghezzi et al., 1996; Sharma et al., 2017), while the majority
of studies measuring cytokine changes after injury have
been done following moderate-to-severe TBL An interesting recent study found in a military population that a mild
TBI was associated with elevated IL-6 and tumor necrosis
factor a (TNFa) in plasma. Intriguingly, the elevated IL-6
and TNFa were associated with PTSD and depression in this
military population (Devoto et al., 2017). In multiple studies,
a moderate-to-severe TBI was found to cause a significant
elevation of IL-6 with the peak of the response occurring
within the first day, and levels returning to baseline within
the first week (Kossmann et al., 1995; Bell et al., 1997a, b;
Pleines et al., 2001; Park et al., 2002; Hayakata et al., 2004;
Shore et al., 2004; Chiaretti et al., 2005, 2008; Buttram et al.,
2007; Frugier et al., 2010; Helmy et al., 2011; Mellergard et
al., 2011; Roberts et al., 2013; Yan et al., 2014a; Aisiku et al.,

2016; Kumar et al., 2016; Nwachuku et al., 2016). TNFa was
found to be significantly elevated in some studies (Otto et
al., 2000; Hayakata et al., 2004; Buttram et al., 2007; Frugier
et al., 2010; Helmy et al., 2011; Roberts et al., 2013; Juengst
et al., 2014; Yan et al., 2014a), and no significant difference
was found in others (Helmy et al., 2011; Aisiku et al., 2016;
Kumar et al., 2016; Nwachuku et al., 2016). Similarly, IL-lb
was found to be elevated in some studies (Park et al., 2002;
Chiaretti et al., 2005; Shiozaki et al., 2005; Buttram et al.,
2007; Chiaretti et al., 2008; Helmy et al., 2011; Mellergard et
al., 2011; Roberts et al., 2013; Nwachuku et al., 2016), while
not in others (Frugier et al., 2010; Aisiku et al., 2016; Kumar
et al., 2016)
The increases in cytokine levels occurring acutely after
injury, as measured in the clinical biomarker studies, have
been shown to correlate with injury severity, and can be
predictive of functional recovery (Kumar et al., 2016; Nwachuku et al., 2016). These properties as a biomarker of injury
severity do not provide direct evidence that these acute cytokine surges seen after the injury are themselves detrimental
to long-term recovery. The increase in cytokines is likely
proportional to the damage caused by the primary injury.
While the clinical literature is limited on the use of anti-cytokine therapy as a neuroprotective following TBI, there is
a fairly extensive preclinical literature showing inhibiting
cytokines acutely after injury can be protective (Simon et
al., 2017). To use an example from our own work, we have
found that a small molecule inhibitor of cytokine overproduction was able to improve functional recovery in a learning and memory task following an experimental brain injury
in mice (Bachstetter et al., 2015).

Prevalence of Depression Following TBI
The compelling relationship of TBI with cognitive impairment and dementia has led to a substantial focus investigating this association by the clinical and scientific communities. Significant psychological disabilities, including
aggression, anxiety, substance abuse and depression, as well
as, physical complications including pain, motor, and balance impairments are also complication of a TBI. Rarely do
the cognitive, psychological, and physical complications of a
TBI occur in isolation (Kumar et al., 2018). For more information on this topic, please refer to an excellent recent review and meta-analysis that illustrates the interrelationship
of post-traumatic depression, and other common secondary
complications of a moderate-to-severe TBI, such as cognitive function and pain (Kumar et al., 2018).
Depression is one of the common psychological sequelae
of TBI, with as high as 56% of individuals having symptoms
of depression at 10-week post-injury (Singh et al., 2018) .
Following a moderate-to-severe injury, the cumulative rate
of major depressive disorder during the first year was found
to be 53%, compared to the rate of major depressive disorder in the general population around 7% (Bombardier et
al., 2010). Further, when studies are limited to concussions,
still up to 22% of people develop depression during the
first 6-months after the injury (Max et al., 2012). A history
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of concussion is associated with 3.3-fold greater risk for a
diagnosis of depression in adolescents (Chrisman and Richardson, 2014), as well as a 2-fold increase in the elderly (Albrecht et al., 2015). On top of single injury risk, the risk for
developing depression is greatly enhanced by the number of
concussions that a person sustains. The relative risk of developing depression increases from 1.5 to 3 when individuals
report less than 3 versus 3+ concussions (Guskiewicz et al.,
2007). Injury severity, number of injuries, age at the time of
injury, and other factors influence the relative likelihood of
post-TBI depression, but few are spared from the risk that a
TBI could contribute to depression.
Like depression in the general population, post-TBI
depression has been found to affect many aspects of life.
Global disability, which reflects both work and non-work
related disability, was found at 6-12 months post-injury to
be significantly correlated with depression severity in a recent study of combat-related concussive TBis in US military
personnel (Mac Donald et al., 2017). In civilians, those individuals that can return to work after the mild TBI, report
that they are less productive and more error prone than before the injury (Silverberg et al., 2018). This reduction in job
performance was associated with depression but not bodily
pain (Silverberg et al., 2018), indicating that something specific about the mechanism of depression following injury is
affecting other cognitive functions. A double-blind, placebo-controlled, randomized clinical trial provided promising
evidence that an SSRI, Sertraline, could reduce the onset of
depression following a TBI when Sertraline was given during
the first 6 months after injury (Jorge et al., 2016). An independent double-blind, placebo-controlled study did not find
a significant effect of Sertraline on major depression after a
TBI; however, the study did find that cognitive function was
improved (Fann et al., 2017). More research is clearly warranted to understand the mechanism ofpost-TBI depression
as the evidence strongly suggest a critical role of depression
in the squeal of TBI, including disability, work productivity,
and cognitive function.

Inflammatory Theory of Depression
Could depression be an inflammatory-mediated and evolutionarily conserved mechanism to TBI? A recent review paper by Drs. Miller and Raison provided a compelling answer
to this question (Miller and Raison, 2016). A primary tenet
of their treatise is that inflammation signals to the organism
to decrease activity, to allow time to fight infection, heal
from wounds, and avoid further pathogen exposure. Arguably, everyone has experienced an inflammatory state of depression, typically during cold and flu season. This response
is not limited to acute inflammatory responses but carries
over to chronic inflammatory diseases. Indeed, sickness
behavior shares many hallmarks of major depressive disorder, such as social withdrawal, and anhedonia (Dantzer et
al., 2008; Miller and Raison, 2016). The difference between
chronic inflammatory disease and acute inflammation associated with infection and their link with depression may
involve the mechanisms of clearing the infection. The sick-

ness behavior associated with a viral infection and its concomitant increase in inflammation, for example, is transient.
Depressive-like symptoms resolve as the infection clears. In
the case of aging, cardiovascular disease, stress, Alzheimer's
disease, and TBI, however, the stimulus that is inducing the
proinflammatory state and the linked depressive-like symptoms does not readily clear like a viral infection, instead a
protracted or even chronic low-grade response remains.
While the levels of inflammatory cytokines, for example, will
be much lower in the chronic disease states, than following a
serious infection, they are nevertheless elevated above physiological levels and thus should be considered as pathophysiological. Evidence in support of the involvement of inflammation in depression comes from three main observations,
as described below.
The first line of evidence supporting the inflammatory
theory of depression is correlative and relies on the presence
of elevated cytokines in the blood of depressed individuals
compared to healthy controls. While correlative, the results
are nevertheless impressive, as summarized in a number
of excellent reviews and meta-analyses (Kohler et al., 2017,
2018; O'Brien et al., 2007; Leighton et al., 2018). Specifically,
a meta-analysis of 82 studies showed that peripheral levels
of numerous cytokines and chemokines, including IL-6 and
TNFa, were elevated in people with major depressive disorder compared to healthy controls (Kohler et al., 2017). A
subsequent meta-analysis furthered the association between
cytokines and depression as they found that the use of anti-depression medication was associated with a reduction
in peripheral inflammatory cytokine levels (Kohler et al.,
2018). It has also been found that increased proinflammatory molecules in systemic circulation are associated with
reduced efficacy of anti-depressants (O'Brien et al., 2007;
Leighton et al., 2018). While the evidence is persuasive, a
number of questions are raised, the most critical being; how
is the depression leading to elevated systemic inflammation,
and how does systemic inflammatory response affect the
neurocircuitry to induce depressive behaviors?
In the review by Drs. Miller and Raison, they propose
three routes to transmit inflammatory signals between
the periphery and the central nervous system (CNS): 1) a
humoral route where cytokines, chemokines, and other inflammatory molecules move back and forth from the blood
and brain, potentially through circumventricular organs; 2)
a cellular route where activation of monocytes/macrophages
by cytokines and chemokines leads to the recruitment of
cells to the brain; 3) a neural route where peripheral nerves,
such as the vagus, stimulate directly on the immune cells in
the bone marrow and spleen, for example, to activate an immune response (Miller and Raison, 2016).
In the context ofTBI, the elevation of cytokines is likely to
first occur locally within the central nervous system by reactive microglia/macrophages and astrocytes (Figure I). The
CNS inflammation or the primary damaged caused by the
TBI could also alter one of the bidirectional routes of communication between the periphery and the CNS, leading to
a chronic dysregulation of the neuroinflammatory response.
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Regardless of the source of the inflammation, if elevated
cytokines are seen in the blood chronically after TBI, this
could be an indicator of individuals that should be evaluated
for depression and may predict the success of treatment to
reduce the depression.
The second line of evidence comes from the therapeutic
use of cytokines. Type I interferons used in the treatment
of hepatitis and multiple sclerosis are strongly associated
with the development of depression, with as much as 80% of
patients on Type I interferon therapy developing depression
(Raison et al., 2005). Not all individuals are equally susceptible to this interaction; for example, patients that have a prior
history of mood disturbances are at a greater risk for developing depression with Type I interferon treatment (Raison
et al. , 2005) . Similarly, in TBI having a prior history of
pre-morbid psychiatric problems prior to the injury is also a
risk factor for depression after the injury (Bowen et al., 1998;
Rao et al., 2010; Rapoport, 2012). These findings suggest that
some individuals, either due to genetics, age, injury, disease
or psychosocial factors have a heightened or otherwise dysregulated response to inflammatory molecules. Thus, two
hits - predisposition towards inflammation and an acute
insult - could tip the balance towards the development of
depression.
The third line of evidence comes from clinical trials where
anti-cytokine treatment has been shown to reduce depression compared to control groups. Much of this evidence
comes from studies where anti-cytokine therapy was used
for the treatment of autoimmune disorders, such as psoriasis, rheumatoid arthritis, and Crohn's disease. As summarized in a systematic review and meta-analysis (Kappelmann
et al., 2018), anti-cytokine treatment was found to have a
significant reduction in depression symptoms compared to
placebo, across the 16 studies included in the analysis, with
an effect estimate of 0.4. To date a single randomized controlled trial has been completed using Infliximab, a TNFablocking antibody, in treatment-resistant depression. While
blocking TNFa showed no significant effect on reducing
depression, a secondary analysis showed that in a subgroup
of participants that had elevated C-reactive protein levels (a protein associated with increases in inflammation),
there was a significant effect of Infliximab treatment on
depression symptoms (Raison et al., 2013). While not directly affecting cytokine signaling, other studies have found
beneficial effects of adding nonsteroidal anti-inflammatory
drugs (NSAIDs) to SSRI therapy (Kappelmann et al., 2018).
NSAIDs, in addition to inhibition of prostaglandin synthesis, are able to cross the cell membrane to block various
signaling cascades important for the inflammatory response
(Diaz-Gonzalez and Sanchez-Madrid, 2015) . Moreover,
minocycline, an antibiotic with immunomodulatory properties, was shown in a recent meta-analysis to have significant
antidepressant activity (Rosenblat and McIntyre, 2018).
As depression is a complex disorder, with many different
potential comorbidities, but common symptomology, there
is a need to consider multiple theories for the pathogenic
mechanisms of depression. With the evidence presented

here, the inflammatory theory of depression shows great
promise. As such, there are currently a number of active
clinical trials investigating anti-cytokine interventions for
the treatment of depression (NCT03004443, NCT03006393,
NCT02765100, NCT02456948). While there has been ample
evidence of the involvement of cytokines following TBI and
a link with post-traumatic depression, there is currently no
information available about active or completed trials using
anti-cytokine treatment for depression following a TBI.

Neuromodulatory Mechanism of TNFa and
IL-1 ~ in Regulating Synaptic Function
Beyond their role in immune function, cytokines have numerous roles in regulating neuronal function, which occur
at the synapse (Figure 2). What is telling about the importance of cytokines as neuromodulators, is the highly specific
mechanisms by which cytokines alter the function of different subsets of neurons. For instance, high levels of IL-1 and
TNFa have been shown to impair long-term potentiation
(LTP) induction and maintenance, but low levels of IL-1
and TNFa are necessary for LTP induction and maintenance (Murray and Lynch, 1998; Ross et al., 2003; Stellwagen and Malenka, 2006; Mori et al., 2014). Further, and
specifically relevant for the role of cytokines in depression,
IL-1 and TNFa have important roles in serotonergic signaling (Ramamoorthy et al., 1995; Mossner et al., 1998; Zhu et
al., 2005, 2006, 2010; Steiner et al., 2008) (Figure 2). These
cytokines have been shown to directly regulate the serotonin
transporter (SERT) through a mechanism dependent on
p38 mitogen activated protein kinase (MAPK) pathway, via
increased production of SERT and increased localization of
SERT to the membrane (Ramamoorthy et al., 1995; Mossner
et al., 1998; Zhu et al., 2005, 2006, 2010; Steiner et al., 2008)
(Figure 2B).
The effects of cytokines on neuronal modulation are
concentration dependent, where physiological levels of cytokines are necessary to facilitate memory formation (V ezzani and Viviani, 2015). Acute increases in cytokines may
increase awareness and sensory functions (Liu and Quan,
2018), while chronic increases cytokines impair synaptic
function (Rogers et al., 2011; Bachstetter et al., 2012; Furman
et al., 2012). What follows is a review of the mechanisms by
which TNFa and IL-1 have been shown to modulate neuronal function at the synapse.
TNFa is produced as a transmembrane protein that can
be cleaved from the membrane by TNFa converting enzyme (also known as ADAM17) to produce a soluble cytokine. TNFa signals via two membrane receptors, TNFRl
and TNFR2. The ubiquitously expressed tumor necrosis
factor receptor (TNFR)l can bind both the soluble and
membrane-bound forms of TNFa. TNFRl is implicated in
apoptotic, proinflammatory, and pathological processes, as
well as neuronal signaling, in response to TNFa activation
(Konefal and Stellwagen, 2017). TNFR2 has a restricted
expression, in comparison to TNFRl, and is found on endo-
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Figure I The effect of traumatic brain injury (TBI) on acute cytokine response, and chronic cytokine dysregulation.
(a) A TBI causes local reactive microglia/macrophages and astrocytes (b). Humoral, cellular, and neural routes (c) lead to increase in local and systemic cytokines. The profile of the different cytokines (for example, interleukin (IL)-I, IL-6, and tumor necrosis factor a (TNFa)), indicated by the
blue, orange, and green dots, have slightly different temporal patterns and max amplitude, but in general, follow a similar profile. (d) The acute inflammatory response to injury results in a surge of cytokines within the first hours-to-days after injury, which can be easily detected by biomarker
assays (pink box). After the first week post-injury (e), cytokines fall below the level of sensitivity for most biomarker assays, but potentially remain
above physiological levels (green box). Compounding factors, such as psychosocial stress and infection, may result in secondary spikes in inflammatory cytokines as measured in biomarker assays (f). Regardless, of the ability to measure cytokines in biomarker assays, therapeutically targeting
the chronic dysregulated cytokines during the months-to-years after injury (g), could reduce cognitive, psychological, and physical complications
of a TBI. Future studies are warranted to test this prediction. However, as cytokines have essential physiological functions, it will be necessary to
have selective therapeutics that restore the physiological balance of cytokines, and not pan-immune suppression.
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Figure 2 Mechanisms by which interleukin I (IL-I) and tumor necrosis factor (TNF) can directly regulate neuronal synaptic function.
(A) IL-1 and TNFa regulate the excitatory and inhibitory neurotransmitter balance. Hyperphysiological levels of cytokines, such as following
a traumatic brain injury (TBI), increase excitatory (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMAPR) and N-methyl-D-aspartic acid receptor (NMDAR)) neurotransmission, while decreasing inhibitory (y-aminobutyric acid (GABA) A receptor (GABAAR))
neurotransmission. Cytokines can also affect the release of glutamate (Glu) from neurons, and the uptake and release of glutamate from astrocytes. (B) IL-I and TNFa also increase the activity of the serotonin transporter (SERT), leading to a decrease in serotonin (5-HT) at the synapse.
(C) Members of the IL- I family of proteins are also involved in synapse formation and stabilization, and IL- I signaling can regulate this process.
EAAT2: Excitatory amino acid transporter 2; IL-IRI : IL-I receptor I; IL-IRAPLI : IL-I-receptor accessory protein like I; IL-IRAcP: IL-I receptor
accessory protein; TNFRl: TNF receptor l; JNK: c-Jun terminal kinase; system
cystine/glutamate antiporter system.
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thelial cells, immune cells, and some neuronal populations
(McCoy and Tansey, 2008). TNFR2 is implicated in prosurvival, and immune suppression. The membrane-bound form
ofTNFa is the most potent activator ofTNFR2 (Grell et al.,
1995). Following brain and spinal cord injury, TNFR2 has
been shown to be neuroprotective and promote regeneration (Sullivan et al., 1999; Mironets et al., 2018). The effects
of TNFa on synaptic function are thought to occur through
TNFRl signaling (Stellwagen et al., 2005; Pribiag and Stellwagen, 2013).
In the hippocampus, TNFa has significant effects on
glutamate signaling, by altering the expression, composition, and phosphorylation of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), which
effect duration of AMPAR-mediated spontaneous excitatory
postsynaptic currents (Bernardino et al., 2005; Stellwagen
et al., 2005; Lai et al., 2006; Stellwagen and Malenka, 2006;
Leonoudakis et al., 2008; Sama et al., 2012; Mandolesi et al.,
2013). The effects ofTNFa on AMPAR activity appear to be
concentration and exposure length dependent. For example, following acute exogenous exposure of TNFa, a rapid
increase in AMP AR surface expression and activity have
been reported (Beattie et al., 2002; Stellwagen et al., 2005;
Stellwagen and Malenka, 2006). In contrast, chronic exposure to low levels of TNFa, as in the case of normal aging,
decreases AMPARs (Sama et al., 2012). Mechanistically, the
regulatory effects of TNFa on AMPARs has been proposed
to occur via phosphatidylinositol 3-kinase (PBK), and p38
MAPK (Pribiag and Stellwagen, 2014) (Figure 2A). However, the full signal transduction pathway regulating the effects
of TNFa on AMP AR remains to be defined. The effects of
TNFa on glutamate signaling appear to be independent of
the N-methyl-D-aspartic acid receptor (NMDAR), at least in
the context of acute TNFa exposure (Beattie et al., 2002; He
et al., 2012), and in the context of chronic TNFa seen with
healthy aging (Sama et al., 2012).
In addition to the effects that TNFa has on the excitatory neurotransmission, via the AMP AR, TNFa also effects
y-aminobutyric acid (GABA) A receptor (GABAAR). GABAAR is the principal mediator of inhibitory neurotransmission in the brain. Specifically, TNFa, acting on neurons
causes a rapid internalization of GABAAR, which decreases
the inhibitory synaptic strength (Pribiag and Stellwagen,
2013). The signal transduction pathway regulating the effects
of TNFa on GABAAR also requires p38 MAPK and PI3K
(Pribiag and Stellwagen, 2013) (Figure 2A).
The IL-1 family includes two agonists, IL-la and IL-1~,
which bind to the same receptor (IL-lRl), to cause a similar
biological response. IL- la is released by all cells, when injured or dying, to rapidly activate an inflammatory response.
IL-1~ is mainly produced by immune cells and microglia.
IL-1R2 is a decoy receptor not capable of signaling. In the
brain, an alternative promoter in the IL- lRl gene generates
a functional brain-specific IL-1 receptor called, IL-1R3 (Qian
et al., 2012). IL-lRl is most highly expressed in the brain on
endothelial cells, and neurons (Liu et al., 2015). The canonical IL- lRl signaling pathway requires the IL- lRl accessory

protein subunit (AcP). In the brain, an alternative IL- lRl
co-receptor, called AcPb, was recently identified (Smith et
al., 2009; Huang et al., 2011). IL-lRl and the IL-lRl accessory proteins (AcP, and AcPb) are highly expressed at the
neuronal synapse (Prieto et al., 2015).
At the postsynaptic terminal, similar to TNFa, IL-1 has
been shown to regulate AMP A receptor expression, phosphorylation, and activity (Stellwagen et al., 2005; Lai et al.,
2006; Kawasaki et al., 2008; Mandolesi et al., 2013; Machado
et al., 2018; Tong et al., 2018). In contrast to TNFa, IL-1
has also been found to have significant effects on NMDAR.
IL-I-induces phosphorylation of the NR2A/B subunits
of the NMDAR, as well as altering the cellular localization of AMP AR and NMDAR, via a Src kinase-dependent
mechanism (Viviani et al., 2003; Davis et al., 2006a, b; Sanchez-Alavez et al., 2006; Ghosh et al., 2016; Bertani et al.,
2017; Tong et al., 2018) (Figure 2A). IL-lRl has also been
shown to be physically associated with NR2B (Gardoni et al.,
2011), further illustrating the interaction between IL-1 and
modulating activity at the synapse. Also, at the postsynaptic
terminal, chronic IL-1/IL- lRl signaling pathway reduces
GABAAR-mediated inhibitory postsynaptic currents (Kawasaki et al., 2008; Roseti et al., 2015), which reduces the counterbalance to the excitatory glutamatergic signaling, while
acute stimulation with IL-1 increases membrane expression
of GABAAR, via an AKT and p38 dependent pathway (Serantes et al., 2006; Wang et al., 2012).
At the presynaptic terminal, IL-1 can increase the release
of glutamate (Casamenti et al., 1999). Astrocytes that surround the synapse are also involved in the IL-1 dependent
regulation of glutamate signaling (Figure 2A). IL-1 decreases uptake of extracellular glutamate, via a reduction in the
high-affinity glutamate transporters on the astrocyte, glial
glutamate transporter I/excitatory amino acid transporter
2 (GLT1/EAAT2). The reduction in GLT1/EAAT2 occurs
through enhanced endocytosis, by a calcium/PKC dependent mechanism (Mandolesi et al., 2013; Yan et al., 2014b).
Also at the astrocyte, IL-1 increases the activity of the cystine/ glutamate antiporter System Xe·, leading to increased
release of glutamate from astrocytes (Fogal et al., 2007).
Physical interaction between pairs of presynaptic and
postsynaptic adhesion molecules is known to regulate synapse formation and stabilization (Takahashi and Craig,
2013; Thalhammer and Cingolani, 2014). Currently, less
than ten postsynaptic adhesion molecules have been identified. Interestingly, three of the postsynaptic adhesion molecules belong to the IL-1 family. Specifically, IL-1 receptor
1 accessory protein (IL-lRlAcP) and IL-lRlAcPb, as well
as IL- I -receptor accessory protein like 1 (ILl RAPLl) are
important postsynaptic adhesion molecules, which interact
physically with protein tyrosine phosphatase (PTP) l5 to regulate synaptogenesis and spine stabilization (Yoshida et al.,
2012; Yamagata et al., 2015; Pozzi et al., 2018). IL-1 has been
shown to alter dendritic morphology by signaling through
the IL-lRlAcP(b)/IL-lRlAPLl complex, through a c-Jun
terminal kinase (JNK) pathway (Pavlowsky et al., 2010;
Montani et al., 2017) (Figure 2C).
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When Can Cytokines Be Targeted
Therapeutically after a TBI?
Following fundamental principles of pharmacology, it is
often assumed that it is necessary to target cytokines after
an injury during the peak of their response, or at least while
they are elevated above basal levels. As described, the peak
of cytokines occurs within hours to a day after an injury;
thus, it can be difficult to target cytokines clinically during
this short window. However, blocking cytokines during the
first hours after injury, could prevent the onset of chronic
neuroinflammation, and block excitatory damage to neurons occurring through dysregulation of the glutamate and
GABA signaling (Figure 2) .
As described, in blood and CSF, levels of cytokines stabilize
at or near physiological levels within a week in people after
a brain injury. Similarly, in animal models of TBI, cytokine
levels in brain homogenates return to sham-injured levels
typically within a week (Bachstetter et al., 2013, 2015; Webster et al., 2015). These data would suggest that the effect of
cytokines in the long-term neurological sequelae of the TBI,
is over after the first week of the injury, and treatments that
target cytokines should be used during this period after the
injury. However, we demonstrated in a mouse model of TBI,
that we could promote functional recovery in a learning and
memory task when we started the treatment with a small
molecule cytokine inhibitor one week after the injury (Webster et al., 2015). These data suggest that there are likely local
disruptions in the cytokine signaling network, possibly occurring at the synapse following a TBI, which last much longer
than would be predicted by the biomarker data (Figure 1).
As cytokines act in an autocrine and paracrine manner in
the local tissue milieu, it may not be possible using existing
technology to see changes in the cytokines following TBI at
the circuit level, specifically at the synapse. Neurons, for instance, are 1000 times more sensitive to IL-1, than other cell
types (Huang et al., 2011), so that even changes in IL-1 levels
that are too small to detect with current methods, could have
a profound impact on neuronal physiology. An alternative
hypothesis is that the primary injury or acute cytokine response to the injury increases the sensitivity of cells to the
cytokines so that low amounts of cytokines are producing an
exaggerated response in the injured brain compared to the
uninjured brain (Figure 1). Much more work is warranted
to test these potential mechanisms. Low levels of chronic
cytokine dysregulation are associated with depression, and
clinical evidence has demonstrated that reducing cytokine
signaling has a significant impact on depression (Raison et
al., 2013; Kappelmann et al., 2018).
Animal models of CNS injury have had mixed success in
modeling psychiatric symptoms following a TBI, such as
depressive-like symptoms using tasks such as the forcedswim test and sucrose preference test, as only a few studies
have been able to detect depressive-like symptoms after the
brain injury (Milman et al., 2005; Jones et al., 2008; Malkesman et al., 2013; Fenn et al., 2014, 2015; Petraglia et al.,
2014; Wu et al., 2014; Rowe et al., 2016; Lim et al., 2017a, b;
Tucker et al., 2017). However, depressive-like symptoms in

animal models are likely associated with periods of remission and reestablishment, as seen in people. Moreover, as in
people, animal models may require a secondary challenge
for the TBI-induced depressive-like symptoms to be evident.
For example, an eloquent study found that a subsequent
immune challenge in mice, after the TBI-induced depressive-like behavior had resolved, caused reestablishment of
the depressive-like symptoms (Fenn et al., 2014). As illustrated in Figure 1, during the chronic phase after the brain
injury, a secondary challenge to the system, which has been
primed by the TBI can lead to psychiatric and neurodegenerative conditions (for a review on inflammatory priming
(Witcher et al., 2015)).

Conclusions
As a multifaceted disorder, depression has been associated
with many medical conditions, including diabetes, cancer,
and cardiovascular disease, as well as TBI, and Alzheimer's disease (Lang and Borgwardt, 2013). The biological
underpinnings of depression are not fully understood and
how depression interacts with these different diseases is a
significant topic of study. For approximately one-third of
people with depression, conventional antidepressants are
not effective. Specifically, in major depression after a TBI,
as described earlier, there are conflicting results on the effectiveness of SSRis (Jorge et al., 2016; Fann et al., 2017).
In these individuals, alternative methods of treatment have
been proposed to individualize treatments to find the most
effective pharmacotherapy to alleviate their symptoms. One
such effort to predict response used computer modeling to
improve the likelihood of treatment efficacy (Chekroud et
al., 2016). Animal models have provided further evidence
that increasing and decreasing inflammation after a TBI can
have a reciprocal effect on depressive-like behavior (Fenn et
al., 2014, 2015).
There are numerous theories for biological mechanisms
of depression (Belmaker and Agam, 2008) . Following at
least thirty years of research since the macrophage theory
of depression was initially postulated (Smith, 1991), there is
now mounting evidence demonstrating that inflammatory
pathways contribute to the pathophysiology of depressive
disorders (Dantzer et al., 2008; Miller and Raison, 2016). As
cytokine dysregulation is a hallmark pathology of TBI, the
inflammatory theory of depression is particularly relevant to
mood disorders that develop following a TBI. Determining
how cytokines regulate mood is an exciting area of investigation and may have great potential for treating mood disorders in people that suffered a TBI.
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